Bliss GVS Pharma Reports Q2 FY2026 Results and Appoints New Head-Legal

Bliss GVS Pharma has announced its unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2025, along with a key management appointment.

Financial Highlights

Standalone Results

Metric	Q2 (Rs lakh)	H1 (Rs lakh)
Revenue from operations	19,022.53	38,564.31
Net profit after tax	2,482.76	6,867.29

Consolidated Results

Metric	Q2 (Rs lakh)	H1 (Rs lakh)
Revenue	20,456.50	40,802.68
Net profit	2,095.76	5,372.36

Management Appointment

The Board of Directors has approved the appointment of Mr. Shreekrushna Joshi as Head-Legal and Senior Management Personnel, effective November 6, 2025. Mr. Joshi brings over 15 years of experience in corporate legal, contract management, and secretarial compliance to the role.

Professional Background

Mr. Joshi's extensive experience includes previous positions at:

Mahindra & Mahindra Limited
Mankind Pharma Limited
Other pharmaceutical companies

His appointment is expected to strengthen the company's legal and compliance functions.

The financial results demonstrate Bliss GVS Pharma's performance for the quarter and half-year, while the new appointment signifies the company's commitment to enhancing its management team with experienced professionals.

1 Day	5 Days	1 Month	6 Months	1 Year	5 Years
+7.69%	+0.94%	+8.52%	+25.50%	+3.69%	-2.81%

Bliss GVS Pharma Limited , a prominent player in the pharmaceutical sector, has recently expanded its share capital through the allotment of equity shares under its Employee Stock Option Plan (ESOP). This move underscores the company's commitment to employee incentivization and aligns with its growth strategy.

Key Details of the Allotment

The ESOP Allotment Committee of Bliss GVS Pharma approved the issuance of 33,670 equity shares on November 5, 2025. These shares, each with a face value of Re. 1, were allotted to eligible employees who exercised their stock options under the company's Employee Stock Option Plan 2019 (Bliss GVS ESOP-2019).

Impact on Share Capital

Following this allotment, the company's share capital structure has undergone the following changes:

Aspect	Before Allotment	After Allotment
Total Issued Shares	10,56,88,923	10,57,22,592
Issued Share Capital	Rs. 10,56,88,923	Rs. 10,57,22,592

Financial and Regulatory Aspects

Exercise Price: The shares were allotted at an exercise price of Rs. 43.00 per share, which includes a premium of Rs. 42.00 per share.
Lock-in Period: The newly allotted shares are subject to a lock-in period of six months from the date of allotment, set to expire on May 5, 2026.
Listing: The shares are expected to be listed on both the BSE Limited and the National Stock Exchange of India Limited, where the company's existing shares are traded.
ISIN: The allotted shares carry the ISIN INE416D01022, consistent with the company's existing equity shares.

Regulatory Compliance

This allotment is in compliance with the SEBI (Share Based Employee Benefits and Sweat Equity) Regulations, 2021. The company has duly informed the stock exchanges about this corporate action, adhering to the principles of transparency and regulatory disclosure.

Implications for Investors and Employees

For existing shareholders, this allotment represents a marginal dilution of 0.03% in their shareholding. However, it also signifies the company's focus on aligning employee interests with those of the shareholders, potentially driving long-term value creation.

For the employees who received these shares, it presents an opportunity to participate in the company's equity and benefit from its future growth, subject to the specified lock-in period.

As Bliss GVS Pharma continues to navigate the dynamic pharmaceutical landscape, this ESOP allotment serves as a testament to its strategy of fostering employee engagement and retention through equity participation.